The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Clinical treatment of psoriasis remains challenging because of possible long‐term drug toxicities and loss of therapeutic effects over time. CX‐5461 is a novel selective inhibitor of RNA polymerase I. Our previous studies have shown that CX‐5461 has potent anti‐inflammatory effects. Here we investigated whether CX‐5461 could inhibit the development of imiquimod‐induced experimental psoriasis in mice...
Background and Purpose
CX‐5461 is a novel selective RNA polymerase I (Pol I) inhibitor. Previously, we found that CX‐5461 could inhibit pathological arterial remodelling caused by angioplasty and transplantation. In the present study, we explored the pharmacological effects of CX‐5461 on experimental pulmonary arterial hypertension (PAH) and PAH‐associated vascular remodelling.
Experimental Approach...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.